Recent advances in the pharmacotherapy of schxzophrenia

Herbert Y. Meltzer*, Myung A. Lee, Rakesh Ranjan

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

68 Scopus citations


The major advance in the psychopharmacology of schizophrenia has been the rediscovery of clozapine and the development of other novel antipsychotic drugs, all of which are superior to typical neuroleptic drugs with regard to extrapyramidal symptoms. Clozapine, the best studied of these agents, is also superior in efficacy with regard to psychopathology and cognitive function and has been shown not to cause tardive dyskinesia. A variety of other novel agents, e.g., risperidone, olanazpine, amperozide, seroquel, sertindole, zaprisidone and melperone, must be further studied to establish their efficacy relative to clozapine or the typical neuroleptics, or both. It is likely that these novel agents will displace the typical neuroleptic drugs as the primary treatment of schizophrenia.

Original languageEnglish (US)
Pages (from-to)95-101
Number of pages7
JournalActa Psychiatrica Scandinavica
StatePublished - Nov 1994


  • clozapine
  • neuroleptic drug
  • risperidone

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Recent advances in the pharmacotherapy of schxzophrenia'. Together they form a unique fingerprint.

Cite this